Pancreatic cancer: Dr. Pudlarz praises 'new generation targeted therapy' that inhibits gene mutation

Oliver Farry is pleased to welcome Dr. Thomas Pudlarz, Medical Oncologist and Head of the pancreatic care pathway within the ‘Interception’ program at the Gustave-Roussy Institute. For decades, pancreatic cancer has remained one of oncology’s most formidable challenges. Despite major advances in immunotherapy and precision medicine, treatment for pancreatic cancer remains elusive. The emergence of an experimental targeted therapy is “one of the first improvements in many years” for a disease that remains among the most aggressive and deadliest forms of cancer, explains Dr. Pudlarz.